Arlene Naranjo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arlene Naranjo has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Barry Lynn Shulkin
Department of Radiology, St Jude Children's Research Hospital, Memphis, TN
3 shared publications - Elizabeth A. Mullen
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
2 shared publications - Julie R. Park
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
2 shared publications - Katherine K. Matthay
Department of Pediatrics University of California San Francisco California USA
2 shared publications - Marguerite T. Parisi
Department of Radiology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA
2 shared publications - Steven G. DuBois
Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA
2 shared publications
Latest Publications
- 7 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Impact of Extent of Surgical Resection on Survival in Patients With High-risk Neuroblastoma
Objective: The impact of extent of resection of the primary tumor on outcomes in patients with high-risk neuroblastoma (HRNB) remains uncertain. We evaluated this issue in patients with HRNB treated on a prospective trial of multimodality therapy. Summary of Background Data: Patients with HRNB enrolled on COG ANBL0532 who underwent surgical resection of their primary tumor during induction were included. Extent of resection was defined by the surgeon as complete excision (CE) if ≥90% of the tumor was resected, and incomplete excision (IE) if MYCN -amplified tumors, and those without image-defined risk factors ( P P =0.0016) and OS (61.8%±3.1% vs. 41.1%±6.9%; P =0.0094) and decreased 5-year CILP (12.8%±2.1% vs. 24.8%±5.8%; P =0.0306). When stratified by extent of resection and autologous stem-cell transplant type, patients with CE randomized to tandem transplant had the highest 5-year EFS, while patients with IE and single transplant had inferior outcomes (57.9±5.5% vs. 18.5±11.8%; P =0.0411). Among patients who received immunotherapy CE was associated with improved 5-year EFS. There was no difference in surgical complications between IE and CE. Conclusions: CE of the primary tumor was associated with significantly higher EFS, OS, and decreased CILP, with no increase in surgical complications. As part of a comprehensive, multimodal treatment strategy, complete primary tumor resection when feasible is a critical component of therapy.
- 7 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Impact of Extent of Surgical Resection on Survival in Patients With High-risk Neuroblastoma
Objective: The impact of extent of resection of the primary tumor on outcomes in patients with high-risk neuroblastoma (HRNB) remains uncertain. We evaluated this issue in patients with HRNB treated on a prospective trial of multimodality therapy. Summary of Background Data: Patients with HRNB enrolled on COG ANBL0532 who underwent surgical resection of their primary tumor during induction were included. Extent of resection was defined by the surgeon as complete excision (CE) if ≥90% of the tumor was resected, and incomplete excision (IE) if MYCN -amplified tumors, and those without image-defined risk factors ( P P =0.0016) and OS (61.8%±3.1% vs. 41.1%±6.9%; P =0.0094) and decreased 5-year CILP (12.8%±2.1% vs. 24.8%±5.8%; P =0.0306). When stratified by extent of resection and autologous stem-cell transplant type, patients with CE randomized to tandem transplant had the highest 5-year EFS, while patients with IE and single transplant had inferior outcomes (57.9±5.5% vs. 18.5±11.8%; P =0.0411). Among patients who received immunotherapy CE was associated with improved 5-year EFS. There was no difference in surgical complications between IE and CE. Conclusions: CE of the primary tumor was associated with significantly higher EFS, OS, and decreased CILP, with no increase in surgical complications. As part of a comprehensive, multimodal treatment strategy, complete primary tumor resection when feasible is a critical component of therapy.
- Open Access
- 8 August 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (15)
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor
Wilms’ tumor is the most common type of childhood kidney cancer. To improve risk stratification and identify novel therapeutic targets for patients with Wilms’ tumor, we used high-resolution mass spectrometry proteomics to identify urine tumor markers associated with Wilms’ tumor relapse. We determined the urine proteomes at diagnosis of 49 patients with Wilms’ tumor, non–Wilms’ tumor renal tumors, and age-matched controls, leading to the quantitation of 6520 urine proteins. Supervised analysis revealed specific urine markers of renal rhabdoid tumors, kidney clear cell sarcomas, renal cell carcinomas as well as those detected in patients with cured and relapsed Wilms’ tumor. In particular, urine prohibitin was significantly elevated at diagnosis in patients with relapsed as compared with cured Wilms’ tumor. In a validation cohort of 139 patients, a specific urine prohibitin ELISA demonstrated that prohibitin concentrations greater than 998 ng/mL at diagnosis were significantly associated with ultimate Wilms’ tumor relapse. Immunohistochemical analysis revealed that prohibitin was highly expressed in primary Wilms’ tumor specimens and associated with disease stage. Using functional genetic experiments, we found that prohibitin was required for the growth and survival of Wilms’ tumor cells. Overexpression of prohibitin was sufficient to block intrinsic mitochondrial apoptosis and to cause resistance to diverse chemotherapy drugs, at least in part by dysregulating factors that control apoptotic cytochrome c release from mitochondrial cristae. Thus, urine prohibitin may improve therapy stratification, noninvasive monitoring of treatment response, and early disease detection. In addition, therapeutic targeting of chemotherapy resistance induced by prohibitin dysregulation may offer improved therapies for patients with Wilms’ and other relapsed or refractory tumors.
- 8 August 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (15)
Open AccessProhibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor
Wilms’ tumor is the most common type of childhood kidney cancer. To improve risk stratification and identify novel therapeutic targets for patients with Wilms’ tumor, we used high-resolution mass spectrometry proteomics to identify urine tumor markers associated with Wilms’ tumor relapse. We determined the urine proteomes at diagnosis of 49 patients with Wilms’ tumor, non–Wilms’ tumor renal tumors, and age-matched controls, leading to the quantitation of 6520 urine proteins. Supervised analysis revealed specific urine markers of renal rhabdoid tumors, kidney clear cell sarcomas, renal cell carcinomas as well as those detected in patients with cured and relapsed Wilms’ tumor. In particular, urine prohibitin was significantly elevated at diagnosis in patients with relapsed as compared with cured Wilms’ tumor. In a validation cohort of 139 patients, a specific urine prohibitin ELISA demonstrated that prohibitin concentrations greater than 998 ng/mL at diagnosis were significantly associated with ultimate Wilms’ tumor relapse. Immunohistochemical analysis revealed that prohibitin was highly expressed in primary Wilms’ tumor specimens and associated with disease stage. Using functional genetic experiments, we found that prohibitin was required for the growth and survival of Wilms’ tumor cells. Overexpression of prohibitin was sufficient to block intrinsic mitochondrial apoptosis and to cause resistance to diverse chemotherapy drugs, at least in part by dysregulating factors that control apoptotic cytochrome c release from mitochondrial cristae. Thus, urine prohibitin may improve therapy stratification, noninvasive monitoring of treatment response, and early disease detection. In addition, therapeutic targeting of chemotherapy resistance induced by prohibitin dysregulation may offer improved therapies for patients with Wilms’ and other relapsed or refractory tumors.
- 23 September 2017
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (2) , 292-305
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0–6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of ≤3 was the most useful predictor across trials. A SIOPEN score ≤ 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores ≤3 were 47% ± 7% versus 26% ± 3% for higher scores at diagnosis (p < 0.007) and 36% ± 4% versus 14% ± 4% (p < 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores ≤3 of 51% ± 7% versus 34% ± 4% for higher scores (p < 0.001) at diagnosis and 43% ± 5% versus 16% ± 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores ≤3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score > 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.
- 23 September 2017
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (2) , 292-305
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0–6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of ≤3 was the most useful predictor across trials. A SIOPEN score ≤ 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores ≤3 were 47% ± 7% versus 26% ± 3% for higher scores at diagnosis (p < 0.007) and 36% ± 4% versus 14% ± 4% (p < 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores ≤3 of 51% ± 7% versus 34% ± 4% for higher scores (p < 0.001) at diagnosis and 43% ± 5% versus 16% ± 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores ≤3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score > 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10526
Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG).
10526 Background: Prior investigations suggest that neuroblastomas (NBL) that do not accumulate MIBG (MIBG non-avid) may have more favorable features compared to MIBG avid tumors. We compared clinical/biologic features and clinical outcomes between patients with MIBG non-avid vs. avid NBL. Methods: A retrospective analysis was performed of patients with metastatic high- or intermediate-risk NBL treated on COG protocols A3973 or A3961, respectively. A3973 patients had baseline MIBG scans centrally reviewed (n = 306). A3961 patients with bone metastasis at baseline were included (n = 37). Comparisons of clinical/biological features according to MIBG avidity were made with chi-squared or Fisher exact tests. Event-free survival (EFS) was compared using log-rank tests and modeled using Cox models. Results: Thirty of 343 patients (8.7%) in the analytic cohort had MIBG non-avid NBL (n = 1 from A3961 and n = 29 from A3973). Non-avid tumors were less likely to be adrenal primary tumors (34.5% vs. 57.2%; p = 0.02) or have bone metastases (36.7% vs. 61.7%; p = 0.008) and were more likely MYCN amplified (53.8% vs. 32.6%; p = 0.03). The rate of positivity for urine catecholamine levels (available from A3973 only) was lower in patients with non-avid NBL (66.7% vs. 91%; p < 0.001). Patients with MIBG non-avid NBL had a 5-year EFS of 50.0% compared to 38.7% for patients with MIBG avid NBL (p = 0.03). On backward-selected multivariate testing in high-risk patients, MIBG avidity was the sole adverse prognostic factor for EFS identified (hazard ratio 1.77; 95% confidence interval 1.04 – 2.99; p = 0.03); MYCN status, age, grade, MKI, and ploidy were not prognostic. Conclusions: MIBG non-avid NBL represents a distinct clinical subgroup with lower rates of adrenal primary tumors, bone metastasis, and catecholamine secretion. Despite being more likely to have MYCN amplified tumors, patients with MIBG non-avid NBL have superior outcomes compared to patients with MIBG avid NBL.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10526
Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG).
10526 Background: Prior investigations suggest that neuroblastomas (NBL) that do not accumulate MIBG (MIBG non-avid) may have more favorable features compared to MIBG avid tumors. We compared clinical/biologic features and clinical outcomes between patients with MIBG non-avid vs. avid NBL. Methods: A retrospective analysis was performed of patients with metastatic high- or intermediate-risk NBL treated on COG protocols A3973 or A3961, respectively. A3973 patients had baseline MIBG scans centrally reviewed (n = 306). A3961 patients with bone metastasis at baseline were included (n = 37). Comparisons of clinical/biological features according to MIBG avidity were made with chi-squared or Fisher exact tests. Event-free survival (EFS) was compared using log-rank tests and modeled using Cox models. Results: Thirty of 343 patients (8.7%) in the analytic cohort had MIBG non-avid NBL (n = 1 from A3961 and n = 29 from A3973). Non-avid tumors were less likely to be adrenal primary tumors (34.5% vs. 57.2%; p = 0.02) or have bone metastases (36.7% vs. 61.7%; p = 0.008) and were more likely MYCN amplified (53.8% vs. 32.6%; p = 0.03). The rate of positivity for urine catecholamine levels (available from A3973 only) was lower in patients with non-avid NBL (66.7% vs. 91%; p < 0.001). Patients with MIBG non-avid NBL had a 5-year EFS of 50.0% compared to 38.7% for patients with MIBG avid NBL (p = 0.03). On backward-selected multivariate testing in high-risk patients, MIBG avidity was the sole adverse prognostic factor for EFS identified (hazard ratio 1.77; 95% confidence interval 1.04 – 2.99; p = 0.03); MYCN status, age, grade, MKI, and ploidy were not prognostic. Conclusions: MIBG non-avid NBL represents a distinct clinical subgroup with lower rates of adrenal primary tumors, bone metastasis, and catecholamine secretion. Despite being more likely to have MYCN amplified tumors, patients with MIBG non-avid NBL have superior outcomes compared to patients with MIBG avid NBL.
- 15 February 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (7) , 1041-1045
Comparison of 123I‐metaiodobenzylguanidine (MIBG) and 131I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group
Background 123I‐metaiodobenzylguanidine (MIBG) scans are preferable to 131I‐MIBG for neuroblastoma imaging as they deliver less patient radiation yet have greater sensitivity in disease detection. Both 123I‐MIBG and 131I‐MIBG scans were used for disease assessments of neuroblastoma patients enrolled on Children's Oncology Group (COG) high‐risk study A3973. The hypothesis was that 123I‐MIBG and 131I‐MIBG scans were sufficiently similar for clinical purposes in terms of ability to predict survival. Procedure Patients enrolled on COG A3973 with stage 4 disease who completed 123I‐MIBG or 131I‐MIBG scans at diagnosis, post‐induction, post‐transplant, or post‐biotherapy were analyzed. The performance of the Curie score for each MIBG scan type in predicting survival was evaluated. At each time point, survival curves for 123I‐MIBG versus 131I‐MIBG were compared using the log‐rank test. Results Of the 413 patients on A3973 with at least one MIBG scan, 350 were stage 4. The 5‐year event‐free survival (EFS) and overall survival (OS) rates were 33.4 ± 3.6% and 45.6 ± 4.0% (N = 350). At post‐induction, EFS (P = 0.3501) and OS (P = 0.5337) for 123I‐MIBG versus 131I‐MIBG were not significantly different. Similarly, comparisons at the three other time points were non‐significant. Conclusions We found no evidence of a statistically significant difference in outcome by type of scan. For future survival analyses of MIBG Curie scores, 123I‐MIBG and 131I‐MIBG results may be combined and analyzed overall, without adjustment for scan type. Pediatr Blood Cancer 2011;56:1041–1045.
- 15 February 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (7) , 1041-1045
Comparison of 123I‐metaiodobenzylguanidine (MIBG) and 131I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group
Background 123I‐metaiodobenzylguanidine (MIBG) scans are preferable to 131I‐MIBG for neuroblastoma imaging as they deliver less patient radiation yet have greater sensitivity in disease detection. Both 123I‐MIBG and 131I‐MIBG scans were used for disease assessments of neuroblastoma patients enrolled on Children's Oncology Group (COG) high‐risk study A3973. The hypothesis was that 123I‐MIBG and 131I‐MIBG scans were sufficiently similar for clinical purposes in terms of ability to predict survival. Procedure Patients enrolled on COG A3973 with stage 4 disease who completed 123I‐MIBG or 131I‐MIBG scans at diagnosis, post‐induction, post‐transplant, or post‐biotherapy were analyzed. The performance of the Curie score for each MIBG scan type in predicting survival was evaluated. At each time point, survival curves for 123I‐MIBG versus 131I‐MIBG were compared using the log‐rank test. Results Of the 413 patients on A3973 with at least one MIBG scan, 350 were stage 4. The 5‐year event‐free survival (EFS) and overall survival (OS) rates were 33.4 ± 3.6% and 45.6 ± 4.0% (N = 350). At post‐induction, EFS (P = 0.3501) and OS (P = 0.5337) for 123I‐MIBG versus 131I‐MIBG were not significantly different. Similarly, comparisons at the three other time points were non‐significant. Conclusions We found no evidence of a statistically significant difference in outcome by type of scan. For future survival analyses of MIBG Curie scores, 123I‐MIBG and 131I‐MIBG results may be combined and analyzed overall, without adjustment for scan type. Pediatr Blood Cancer 2011;56:1041–1045.